This study is being done to identify blood tests and symptoms specific to pancreas cancer, which could lead to earlier detection of the disease. Often times with pancreas cancer there is a lack of symptoms or a presentation of
symptoms that are not specific early in the disease. Developing a test that could detect early-stage pancreas cancer, before symptoms develop, could improve the survival rate. There are currently no early detection tools available.
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT03568630.
Locations matching your search criteria
United States
Nebraska
Omaha
University of Nebraska Medical CenterStatus: Active
Contact: Kelsey A. Klute
Phone: 402-559-8500
PRIMARY OBJECTIVES:
I. Generate clinical data and serial blood specimens from subjects who subsequently develop pancreatic ductal adenocarcinoma to identify and validate biomarkers of preclinical disease.
II. Identify clinical features and characterize a metabolic signature of diabetes secondary to underlying PDAC.
III. Characterize a symptom complex which may be specific for early pancreas cancer.
OUTLINE: This is an observational study.
Participants complete questionnaires, undergo collection of blood samples and have their medical records reviewed throughout the study. Participants complete a mix meal tolerance test as clinically indicated.
Participants complete follow-up every 6 months.
Trial PhaseNo phase specified
Trial Typescreening
Lead OrganizationUniversity of Nebraska Medical Center
Principal InvestigatorKelsey A. Klute
